Chugai Pharmaceutical (4519) Q4 2025 earnings summary

Executive summary

• Achieved record-high revenue, operating profit, and net income for FY2025, with revenue at JPY 1,257.9 billion (+7.5% YoY), core operating profit at JPY 623.2 billion (+12.1% YoY), and net income at JPY 451.0 billion (+13.6% YoY); operating margin reached 49.5%.

• Growth was driven by strong exports of Actemra and Hemlibra, robust domestic sales, increased royalty income, and new product launches.

• Management focused on strengthening R&D, accelerating open innovation, and advancing digital transformation, including AI-driven business transformation.

• Opened a U.S. partnering office to enhance global innovation and collaboration.

• Special dividends were paid for the 100th anniversary, resulting in a high payout ratio for 2025.

Financial highlights

• Revenue: JPY 1,257.9 billion (+7.5% YoY); core operating profit: JPY 623.2 billion (+12.1% YoY); net income: JPY 451.0 billion (+13.6% YoY); EPS: JPY 274.02 (+13.6% YoY).

• Domestic sales: JPY 472.4 billion (+2.5% YoY); overseas sales: JPY 605.4 billion (+12.8% YoY); other revenues, including royalties, rose to JPY 180.1 billion.

• Cost to sales ratio improved to 32.6% in 2025; R&D expenses increased to JPY 180.1 billion (+1.8% YoY).

• Operating profit margin reached a record 49.5%, up 2 percentage points year-on-year.

• Positive foreign exchange impact added JPY 49.6 billion to revenue and JPY 44.2 billion to operating profit.

Outlook and guidance

• FY2026 revenue forecast: JPY 1,345 billion (+6.9% YoY); core operating profit: JPY 670 billion (+7.5% YoY); core net income: JPY 485.0 billion (+7.5% YoY); core EPS: JPY 295.00 (+7.7% YoY).

• Domestic product sales expected to rise by JPY 25.6 billion, offsetting NHI price revisions and generic competition; overseas sales to remain flat.

• Dividend for 2025 set at JPY 272 per share (including 100th anniversary dividend); 2026 dividend forecast at JPY 132 per share, with a stable 45% payout ratio.

• Strategic focus on accelerating R&D, digital transformation, and global product launches to achieve sustainable growth.